David A. Siegel Recursion Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 451,745 shares of RXRX stock, worth $3.68 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
451,745
Previous 489,900
7.79%
Holding current value
$3.68 Million
Previous $3.23 Million
5.42%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding RXRX
# of Institutions
341Shares Held
284MCall Options Held
2.83MPut Options Held
3.64M-
Vanguard Group Inc Valley Forge, PA34MShares$277 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.3MShares$263 Million1.91% of portfolio
-
Baillie Gifford & CO24.9MShares$202 Million0.13% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$141 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$119 Million0.44% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.47B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...